Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics


Pacific Biosciences of California, Inc. (PACB): $9.72

-0.39 (-3.86%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PACB POWR Grades

  • PACB scores best on the Value dimension, with a Value rank ahead of 28.31% of US stocks.
  • The strongest trend for PACB is in Value, which has been heading down over the past 178 days.
  • PACB's current lowest rank is in the Stability metric (where it is better than 8.9% of US stocks).

PACB Stock Summary

  • With a price/sales ratio of 17.09, PACIFIC BIOSCIENCES OF CALIFORNIA INC has a higher such ratio than 93.42% of stocks in our set.
  • Over the past twelve months, PACB has reported earnings growth of 130.99%, putting it ahead of 88.2% of US stocks in our set.
  • The volatility of PACIFIC BIOSCIENCES OF CALIFORNIA INC's share price is greater than that of 83.08% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PACIFIC BIOSCIENCES OF CALIFORNIA INC are TUYA, IMAB, ENVX, EFTR, and BCYC.
  • PACB's SEC filings can be seen here. And to visit PACIFIC BIOSCIENCES OF CALIFORNIA INC's official web site, go to www.pacb.com.

PACB Valuation Summary

  • In comparison to the median Healthcare stock, PACB's price/sales ratio is 735% higher, now standing at 16.7.
  • Over the past 147 months, PACB's price/earnings ratio has gone down 0.5.

Below are key valuation metrics over time for PACB.

Stock Date P/S P/B P/E EV/EBIT
PACB 2022-11-25 16.7 3.6 -7.6 -10.3
PACB 2022-11-23 17.1 3.7 -7.8 -10.5
PACB 2022-11-22 17.5 3.8 -8.0 -10.7
PACB 2022-11-21 17.2 3.8 -7.9 -10.6
PACB 2022-11-18 17.5 3.8 -8.0 -10.7
PACB 2022-11-17 17.5 3.8 -8.0 -10.7

PACB Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -129.01%.
  • Its year over year price growth rate is now at -74.88%.
  • The 5 year cash and equivalents growth rate now stands at 310.75%.
Over the past 33 months, PACB's revenue has gone up $46,079,000.

The table below shows PACB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 136.97 -234.353 -299.193
2022-06-30 139.546 -211.956 -205.68
2022-03-31 134.689 -167.105 -175.287
2021-12-31 130.513 -111.18 -181.223
2021-09-30 121.63 -93.735 -36.959
2021-06-30 105.825 -70.887 -77.209

PACB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PACB has a Quality Grade of C, ranking ahead of 52.82% of graded US stocks.
  • PACB's asset turnover comes in at 0.132 -- ranking 67th of 75 Measuring and Control Equipment stocks.
  • TMO, PKI, and PRPO are the stocks whose asset turnover ratios are most correlated with PACB.

The table below shows PACB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.132 0.427 -0.085
2021-03-31 0.169 0.412 -0.129
2020-12-31 0.271 0.413 0.185
2020-09-30 0.355 0.428 -0.409
2020-06-30 0.445 0.411 -0.473
2020-03-31 0.515 0.410 -0.412

PACB Price Target

For more insight on analysts targets of PACB, see our PACB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $45.75 Average Broker Recommendation 1.6 (Moderate Buy)

PACB Stock Price Chart Interactive Chart >

Price chart for PACB

PACB Price/Volume Stats

Current price $9.72 52-week high $23.87
Prev. close $10.11 52-week low $3.85
Day low $9.60 Volume 2,578,600
Day high $10.23 Avg. volume 6,686,059
50-day MA $7.71 Dividend yield N/A
200-day MA $7.16 Market Cap 2.20B

Pacific Biosciences of California, Inc. (PACB) Company Bio


Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.


PACB Latest News Stream


Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream


Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about PACIFIC BIOSCIENCES OF CALIFORNIA INC that investors may wish to consider to help them evaluate PACB as an investment opportunity.

J.P. Morgan Remains a Buy on Pacific Biosciences (PACB)

J.P. Morgan analyst Julia Qin maintained a Buy rating on Pacific Biosciences (PACB - Research Report) yesterday and set a price target of $13.00. The company's shares closed yesterday at $10.63.Qin covers the Healthcare sector, focusing on stocks such as Seer, Invitae, and Singular Genomics Systems. According to TipRanks, Qin has an average return of 2.4% and a 50.00% success rate on recommended stocks. In addition to J.P. Morgan, Pacific Biosciences also received a Buy from Canaccord Genuity's Kyle Mikson CFA in a report issued on November 16. However, on the same day, Piper Sandler maintained a Hold rating on Pacific Biosciences (NASDAQ: PACB).

Howard Kim on TipRanks | November 18, 2022

PacBio to Present at Upcoming Investor Conferences

PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences:

Yahoo | November 11, 2022

PacBio's (PACB) Q3 Earnings Top Estimates, Revenues Lag

PacBio (PACB) witnesses strength in Service and other revenues, along with robust consumable sales, in the third quarter.

Yahoo | November 8, 2022

Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 8.57% and 8.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 7, 2022

PacBio Announces Third Quarter 2022 Financial Results

PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022.

Yahoo | November 7, 2022

Read More 'PACB' Stories Here

PACB Price Returns

1-mo 11.47%
3-mo 65.87%
6-mo 73.57%
1-year -57.85%
3-year 89.11%
5-year 204.70%
YTD -52.49%
2021 -21.13%
2020 404.67%
2019 -30.54%
2018 180.30%
2017 -30.53%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7889 seconds.